---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-009345"
form_type: "8-K"
ticker: "WHWK"
cik: "0001422142"
company_name: "Whitehawk Therapeutics, Inc."
filed_at: "2023-03-28T23:59:59+00:00"
generated_at: "2026-06-17T12:33:53.234359+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Aadi Bioscience reports FY2022 revenue $15.2M; PRECISION-1 data Q2 2023

## Summary
- FY 2022 total revenue $15.2M from FYARRO (10 months); Q4 net product sales $5.2M (+23% QoQ).
- Net loss $60.5M for FY2022 vs $110.1M in FY2021 (prior year incl $74.2M impairment).
- Cash $172.6M at Dec 31, 2022; cash runway into 2025 after $72.5M Q4 financing.
- PRECISION-1 trial preliminary data on TSC1/TSC2 alterations expected Q2 2023.
- Appointed Dr. Mohammad Hirmand to Board; collaboration with Mirati on adagrasib combo trial start Q2 2023.

## SEC filing metadata
- accession: 0001628280-23-009345
- form_type: 8-K
- ticker: WHWK
- cik: 0001422142
- company_name: Whitehawk Therapeutics, Inc.
- filed_at: 2023-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422142/000162828023009345/0001628280-23-009345-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422142/000162828023009345/aadi-20230324.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-009345
- JSON: https://secwatch.observer/filing/0001628280-23-009345.json
- Plain text: https://secwatch.observer/filing/0001628280-23-009345.txt

## Key facts
- Earnings Releases
  Whitehawk Therapeutics, Inc. reported Fiscal year ended December 31, 2022 results: revenue $15.2 million, net income $60.5 million net loss.
  - Period: Fiscal year ended December 31, 2022
  - Revenue: $15.2 million
  - Net income: $60.5 million net loss
  - Result: reported results
  source text: Total revenue for the quarter ended December 31, 2022 was $5.2 million, and $15.2 million for the full-year ended December 31, 2022, resulting from sales of FYARRO. • Net loss for the three months ended December 31, 2022 was $13.9 million as compared to $16.0 million for the three months ended December 31, 2021. Net loss for the full-year 2022 ended December 31, 2022 was $60.5 million, as compared to $110.1 million for the period in 2021 (The prior year included the non-cash impairment charge of $74.2 million related to the acquired contract intangible asset incurred in conjunction with the Aerpio merger).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000162828023009345/0001628280-23-009345-index.htm
- Earnings Releases
  Whitehawk Therapeutics, Inc. reported Three months ended December 31, 2022 results: revenue $5.2 million, net income $13.9 million net loss.
  - Period: Three months ended December 31, 2022
  - Revenue: $5.2 million
  - Net income: $13.9 million net loss
  - Result: reported results
  source text: Total revenue for the quarter ended December 31, 2022 was $5.2 million, and $15.2 million for the full-year ended December 31, 2022, resulting from sales of FYARRO. • Net loss for the three months ended December 31, 2022 was $13.9 million as compared to $16.0 million for the three months ended December 31, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000162828023009345/0001628280-23-009345-index.htm
- Executive change
  Mohammad Hirmand was appointed as Class II Director at Whitehawk Therapeutics, Inc..
  - Action: appointed
  - Role: Class II Director
  source text: On March 24, 2023, Mohammad Hirmand, M.D. was appointed a Class II director by the Board of Directors (the “ Board ”) of the Company, effective March 27, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000162828023009345/0001628280-23-009345-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.